[Therapeutic efficacy and general tolerability of 4-carbomethoxythiazolidine chlorohydrate administered by aerosol in adult patients with catarrhal pathology of otorhinolaryngologic origin].
The test has been performed on 20 patients, aged between 14 and 68 suffering from a catarrhal pathology of otorhinolaryngologic nature for which a mucolitic aerosol therapy was recommended. 4-carbomethoxythiazolidine has been administered with a posology of one bottle twice a day (by aerosol-nebulization) for periods of time ranging from 4 up to 15 days. Together with the 4-carbomethoxythiazolidine treatment, some patients have been administered concomitant drugs. At the end of the tests the development of the most significative symptomatologic parameters has been analysed according to the Wilcoxon test: quantity, kind and characteristics of nasal secretions, nasal obstruction, phlogosis of the nasal and pharyngeal mucosa, hoarseness, difficulty in catarrhal expectoration, hypoacusia, retraction of the tympanic membrane. The final clinic evaluation of the efficacy of 4-carbomethoxythiazolidine, expressed according to the examination of the achieved clinic result, has been "positive" in 17 cases (85%) and "negative" in 3 cases (15%). As for its tolerance, in no case has 4-carbomethoxythiazolidine caused detectable side-effects.
Lomeo
G
G
Divisione Otorinolaringoiatrica e Servizi di Audiologia, Ospedale Vittorio Emanuele II, Catania.
D000293:Adolescent; D000328:Adult; D000336:Aerosols; D000368:Aged; D005100:Expectorants / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010038:Otorhinolaryngologic Diseases / Q000188:drug therapy*; D013844:Thiazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D000336:Aerosols; D005100:Expectorants; D013844:Thiazoles; C070586:4-carbomethoxythiazoline
Efficacia terapeutica e tollerabilità della 4-carbometossitiazolidina cloridrato somministrata per aerosol su pazienti adulti con patologie catarrali di interesse otorinolaringoiatrico.